«Inhibiting mTOR signaling
using everolimus, a targeted therapy, known as a rapalog, for patients with lung and gastroenteropancreatic NETs, has been approved by the FDA.
Finding new treatments is critical because less than 5 percent of patients with pancreatic neuroendocrine tumors respond to
everolimus, the most commonly
used pharmaceutical, François said.